Aside from adherence to ECM compounds, increased integrin α5 levels and downstream signaling via AKT can help tumor cells and facilitate their migration to bone [61], suggesting that integrin α5 may be a prognostic marker of RCC bone metastasis. Here, AKT1 is linked to renal cell carcinoma.